Argenx announces u.s. fda acceptance of biologics license application for subcutaneous efgartigimod in generalized myasthenia gravis with priority review

- prescription drug user fee act (pdufa) target action date is march 2 0 , 2023
ARGX Ratings Summary
ARGX Quant Ranking